title: [Feasibility of alpha-blockers in chronic category III prostatitis].
abstract: Studies were identified on internet by searching on address: http://www.ncbi.nlm.nih.gov/pubmed/ with criteria that studies should be placebo-controlled and randomized in trials of alpha-blockers in chronic category III prostatitis evaluated by symptom-score NIH-CPSI. From 13 clinical studies three were excluded because of not using NIH-CPSI, three were in Chinese language and two were congress abstracts. Analysed were five studies with four or five Jadad scale including 563 patients. Alpha-blockers alfuzosin, terazosin, tamsulosin and doxazosin have been used through 6 weeks and 6 months. Better results were accomplished by less selective alpha-blockers alfuzosin, terazosin and doxazosin through 3-6 months in patients having higher NIH-CPSI score and higher voiding score.
authors: Opća bolnica Zabok. silvio.altarac@vip.hr
authors: Silvio
authors: S
authors: Altarac
authors: Vedran
authors: V
authors: Cindro
authors: Nikola
authors: N
authors: Radović
authors: Zoran
authors: Z
authors: Rajković
authors: Stanko
authors: S
authors: Belina
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D002908:Chronic Disease; D006801:Humans; D008297:Male; D011472:Prostatitis / Q000188:drug therapy*
chemical_list: D000317:Adrenergic alpha-Antagonists